Research Paper Volume 16, Issue 10 pp 9047—9071
Targeting PRKDC activates the efficacy of antitumor immunity while sensitizing to chemotherapy and targeted therapy in liver hepatocellular carcinoma
Figure 2. Immune landscapes of two groups. (A) Comparative box plots illustrating normalized expression levels of chemokines and receptors in two groups. (B) Comparative box plots showcasing normalized expression levels of interleukins and their receptors in two groups. (C) Comparative box plots demonstrating normalized expression levels of interferons and their receptors in two groups. (D) Comparative box plots revealing normalized fraction levels of infiltrated immune cells calculated by CIBERSORT in the two clusters. (E) Comparative box plots displaying normalized expression levels of immune checkpoints in two groups. (F) Comparative box plots presenting ssGSEA scores for immune function signatures between two groups. (G) Submap result for predicting the immunotherapy of anti-CTLA4 and anti-PD1 in C1 and C2 groups (*P < 0.05, **P < 0.01, and ***P < 0.001 determined by Wilcoxon test).